Priority 12 from the Mesothelioma PSP
| UNCERTAINTY: How can the levels of mesothelin (a protein present in mesothelioma cells that can be measured in the blood) best be incorporated in the diagnosis, response and progression of mesothelioma? (JLA PSP Priority 12) | |
|---|---|
| Overall ranking | 12 |
| JLA question ID | 0025/12 |
| Explanatory note | Not available for this PSP |
| Evidence | Systematic review - Cui A, Jin XG, Zhai K, Tong ZH, Shi HZ. Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. BMJ Open. 2014 Feb 24;4(2):e004145. doi: 10.1136/bmjopen-2013-004145 |
| Health Research Classification System category | Cancer |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | Five years ago my blood was analysed by an immunologist who discovered immunity to mesothelin and 5T4, two antigens which express with mesothelioma |
| Comparison | Diagnostics |
| Submitted by | Patient |
| Outcomes to be measured | Diagnosis |
| PSP information | |
|---|---|
| PSP unique ID | 0025 |
| PSP name | Mesothelioma |
| Total number of uncertainties identified by this PSP. | 53 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 16 December 2014 |